1 min read

ID: 288837

Discovery Date: 14 May 2022, 13:10:06 UTC

Published Date: 2022-05-14 10:00:00

Source: PubMed

Link: https://pubmed.ncbi.nlm.nih.gov/35563884/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220514091005&v=2.17.6

Manual Selection: true

Machine Learning Gaussian Naive Bayes Model: false

Abstract

Novel, neuroprotective uses of Copaxone (generic name: glatiramer acetate-GA) are being examined, primarily in neurological conditions involving cognitive decline. GA is a well-studied synthetic copolymer that is FDA-approved for immune-based treatment of relapsing remitting multiple sclerosis (RRMS). Clinical studies have explored the potential mechanism of action (MOA) and outcomes of GA immunization in patients. Furthermore, results from these and animal studies suggest that GA has a direct…

Noun Phrases in Title

  • Glatiramer Acetate Immunomodulation
  • Evidence
  • Neuroprotection
  • Cognitive Preservation
This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by donating what you can to pay for the server costs.